Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis
Open accessAbstract
Background Depression affects approximately one-quarter of people treated with dialysis and is considered an important research uncertainty by patients and health professionals. Treatment for depression in dialysis patients may have different benefits and harms compared to the general population due to different clearances of antidepressant medication and the severity of somatic symptoms associated with end-stage kidney disease (ESKD). Guidelines suggest treatment of depression in dialysis patients with pharmacological therapy, preferably a selective serotonin reuptake inhibitor. This is an update of a review first published in 2005. Objectives To evaluate the benefit and harms of antidepressants for treating depression in adults with ESKD treated with dialysis. Search methods We searched Cochrane Kidney and Transplant's Specialised Register to 20 January 2016 through contact with the Information Specialist using search terms relevant to this review. Selection criteria Randomised controlled trials (RCTs) comparing antidepressant treatment with placebo or no treatment, or compared to another antidepressant medication or psychological intervention in adults with ESKD (estimated glomerular filtration rate Data collection and analysis Data were abstracted by two authors independently onto a standard form and subsequently entered into Review Manager. Risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data were calculated with 95% confidence intervals (9…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In diseases such as epilepsy, inflammatory bowel disease, traumatic brain injury, asthma and chronic obstructive pulmonary disease, few or no RCTs of antidepressant treatment for comorbid MDD have been conducted.
“In other diseases – such as epilepsy, inflammatory bowel disease, traumatic brain injury, asthma and chronic obstructive pulmonary disease – few or no RCTs of antidepressant treatment for comorbid MDD have been conducted295-301”
From Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management (2023) · cites this paper as [296]
The citation lists haven’t been fetched yet
References 146 · Cited by 96
- Authors
- Palmer, S. C., Natale, P., Ruospo, M., Saglimbene, V. M., Rabindranath, K. S., Craig, J. C., & Strippoli, G. F.
- Affiliations
- University of Otago (NZ)
- Diaverum; Medical Scientific Office; Lund Sweden
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Waikato Hospital (NZ)
- The University of Sydney (AU)
- Children's Hospital at Westmead (AU)
- ORCID
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-05-23
- Volume
- 2016
- Issue
- 5
- Pages
- CD004541-CD004541
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC8520741
- OpenAlex
- W2398324399
- Cited by
- 96
- References
- 146
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 12 · 2023: 11 · 2022: 13 · 2021: 9 · 2020: 13 · 2019: 11 · 2018: 6 · 2017: 5 · 2016: 1
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Keywords
- antidepressants, depression, end-stage renal disease, dialysis, selective serotonin reuptake inhibitors, fluoxetine, sertraline, citalopram, escitalopram, hypotension, sexual dysfunction, nausea, quality of life, psychological intervention, placebo comparison, somatic symptoms, hospitalization, suicide risk, end-of-life care, end-of-life decisions, end-of-life communication, end-of-life care planning, advance care planning, palliative care
- MeSH terms
- Adult, Antidepressive Agents, Depression, Fluoxetine, Renal Dialysis, Humans, Kidney Failure, Chronic, Psychotherapy, Quality of Life, Citalopram, Randomized Controlled Trials as Topic, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
